Coastline Trust Co Sells 6,260 Shares of Becton, Dickinson and Company $BDX

Key Points

• Coastline Trust Co reduced its stake in Becton, Dickinson and Company by 66.8%, now holding only 3,109 shares valued at approximately $536,000.
• Becton, Dickinson and Company reported $3.68 earnings per share for the last quarter, exceeding analyst expectations, with a revenue increase of 10.4% year-over-year.
• The company announced a quarterly dividend of $1.04 per share, reflecting an annualized yield of 2.3% and a payout ratio of 74.82%.

Coastline Trust Co cut its holdings in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 66.8% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,109 shares of the medical instruments supplier's stock after selling 6,260 shares during the quarter. Coastline Trust Co's holdings in Becton, Dickinson and Company were worth $536,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in BDX. GQG Partners LLC purchased a new position in Becton, Dickinson and Company in the 1st quarter worth $689,833,000. Vanguard Group Inc. grew its stake in shares of Becton, Dickinson and Company by 4.7% during the first quarter. Vanguard Group Inc. now owns 28,002,802 shares of the medical instruments supplier's stock valued at $6,414,322,000 after buying an additional 1,259,750 shares during the last quarter. Nuveen LLC purchased a new position in shares of Becton, Dickinson and Company in the first quarter worth about $211,097,000. Kingstone Capital Partners Texas LLC bought a new stake in shares of Becton, Dickinson and Company in the 2nd quarter valued at about $155,080,000. Finally, GAMMA Investing LLC boosted its holdings in Becton, Dickinson and Company by 29,654.0% during the 1st quarter. GAMMA Investing LLC now owns 744,445 shares of the medical instruments supplier's stock valued at $170,523,000 after acquiring an additional 741,943 shares during the period. Hedge funds and other institutional investors own 86.97% of the company's stock.

Becton, Dickinson and Company Stock Up 2.2%

Shares of Becton, Dickinson and Company stock opened at $184.59 on Friday. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 12-month low of $163.33 and a 12-month high of $251.99. The company has a market cap of $52.91 billion, a P/E ratio of 33.20, a PEG ratio of 1.49 and a beta of 0.27. The company's fifty day simple moving average is $188.27 and its two-hundred day simple moving average is $188.72.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, beating analysts' consensus estimates of $3.40 by $0.28. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The firm had revenue of $5.51 billion for the quarter, compared to analyst estimates of $5.50 billion. During the same quarter in the previous year, the firm posted $3.50 EPS. The company's revenue for the quarter was up 10.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Research analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th will be issued a dividend of $1.04 per share. The ex-dividend date is Monday, September 8th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.3%. Becton, Dickinson and Company's dividend payout ratio is 74.82%.

Analysts Set New Price Targets

BDX has been the topic of a number of analyst reports. Piper Sandler reaffirmed a "neutral" rating and issued a $200.00 price target (up from $185.00) on shares of Becton, Dickinson and Company in a research note on Friday, August 8th. Royal Bank Of Canada began coverage on shares of Becton, Dickinson and Company in a report on Thursday. They issued a "sector perform" rating and a $211.00 target price on the stock. Argus upped their price target on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Morgan Stanley increased their price target on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an "overweight" rating in a research report on Monday, August 11th. Finally, Wells Fargo & Company boosted their price objective on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an "equal weight" rating in a research report on Friday, August 8th. Four research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $213.09.

Insider Activity at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 1,185 shares of the stock in a transaction that occurred on Friday, July 18th. The stock was sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the transaction, the executive vice president owned 4,887 shares of the company's stock, valued at approximately $881,077.23. This represents a 19.52% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Claire Fraser sold 917 shares of Becton, Dickinson and Company stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the sale, the director owned 22,226 shares in the company, valued at $4,167,375. This represents a 3.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 2,965 shares of company stock valued at $551,536 in the last three months. Corporate insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.